Cerus Co. (CERS) Rating Increased to Hold at BidaskClub
Cerus Co. (NASDAQ:CERS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday.
Other equities research analysts have also issued reports about the company. Cowen and Company dropped their price target on Cerus from $9.50 to $7.00 and set an “outperform” rating for the company in a research note on Monday, April 17th. Cantor Fitzgerald set a $9.00 price target on Cerus and gave the stock a “buy” rating in a research note on Thursday, May 4th. Zacks Investment Research lowered Cerus from a “hold” rating to a “sell” rating in a research note on Friday, May 26th. BTIG Research restated a “buy” rating and set a $5.00 price target on shares of Cerus in a research note on Sunday, May 28th. Finally, ValuEngine lowered Cerus from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $7.25.
Cerus (CERS) traded up 2.6946% during trading on Tuesday, hitting $2.5725. The stock had a trading volume of 712,858 shares. The firm’s market cap is $267.38 million. Cerus has a one year low of $1.93 and a one year high of $7.48. The stock’s 50-day moving average is $2.33 and its 200 day moving average is $3.45.
Cerus (NASDAQ:CERS) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). The firm had revenue of $9.53 million during the quarter, compared to analyst estimates of $9.14 million. Cerus had a negative return on equity of 169.65% and a negative net margin of 152.64%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.18) earnings per share. Equities analysts anticipate that Cerus will post ($0.68) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/08/cerus-co-cers-rating-increased-to-hold-at-bidaskclub.html.
A number of large investors have recently made changes to their positions in CERS. First Manhattan Co. raised its stake in shares of Cerus by 31.3% in the second quarter. First Manhattan Co. now owns 42,000 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 10,000 shares in the last quarter. Marathon Capital Management raised its stake in shares of Cerus by 32.4% in the first quarter. Marathon Capital Management now owns 24,500 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 6,000 shares in the last quarter. Budros Ruhlin & Roe Inc. raised its stake in shares of Cerus by 41.7% in the first quarter. Budros Ruhlin & Roe Inc. now owns 25,470 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 7,500 shares in the last quarter. Bellevue Group AG purchased a new stake in shares of Cerus during the first quarter valued at approximately $134,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Cerus during the first quarter valued at approximately $137,000. Institutional investors own 65.09% of the company’s stock.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Co. and related companies with MarketBeat.com's FREE daily email newsletter.